Skip to main content
U.S Department of Health and Human Services (HHS) National Institutes of Health
Español
HomeFind Clinical TrialsBrain Safe: Reducing Exposure to Drugs Linked to Alzheimer's
Find more clinical trials

Brain Safe: Reducing Exposure to Drugs Linked to Alzheimer's

Start: October 16, 2019
End: February 28, 2024
Enrollment: 700

What Is This Study About?

Anticholinergics are a class of drugs used to treat many medical problems and have been associated with a higher risk of dementia. This study will test the effectiveness of an application called Brain Safe to reduce older adults' exposure to prescription anticholinergics and improve function and quality of life. Participants will be randomly assigned to use either the Brain Safe application or a medication list application for one year. The applications will be loaded on a smartphone provided by the study or the participant. Brain Safe provides conversation starters for older adults to talk with their doctor about any use of anticholinergics and potential for changing or stopping the prescription. It also includes a medication list, risk calculator, and educational content.

Do I Qualify To Participate in This Study?

Minimum Age: 60 Years

Maximum Age: N/A

Must have:

  • Primary care visit at Eskenazi Health or Indiana University Health in past year
  • English-speaking
  • At least one prescription for a strong anticholinergic medication in past year and currently using it
  • Community-dwelling in Central Indiana
  • Not cognitively impaired
  • Not terminally ill
  • Not sensory impaired (after correction)

Must NOT have:

  • Permanent resident of an extended care facility (nursing home); independent or assisted living is allowed if managing own medication
  • Diagnosis of Alzheimer's disease or related dementia or taking dementia medications
  • Diagnosis of schizophrenia, bipolar disorder, or schizoaffective disorder
  • Involvement in another clinical trial that would prevent or interfere with study objectives
  • Sensory or other impairment prohibiting the use of a mobile touchscreen device or other study activity

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Christian Vallejo
Kimberly Trowbridge

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Indiana
IU Health
Indianapolis, IN 46202
Recruiting
Jose Azar, MD
Richard John Holden
Indianapolis, IN 46202
Recruiting
Richard J Holden, PhD

Who Sponsors This Study?

Lead: Indiana University

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT04121858